Abstract:Background The pathogenesis and etiology of systemic sclerosis (SSc) are complex and poorly understood. To date, several studies have demonstrated that the activation of the immune system undoubtedly plays a pivotal role in SSc pathogenesis. Activated immune effector T cells contribute to the release of various pro-inflammatory cytokines and drive the SSc-specific autoantibody responses. This, and a profibrotic environment, are all-important components of abnormal active immune responses that can lead to pathological disorders of SSc. CD11a is essential to inflammatory and immune responses, regulating adhesive and co-stimulatory interactions between CD4 + T cells and other cells. Although CD11a is overexpressed in SSc patients, the mechanisms leading to this overexpression and its consequences remain unclear. DNA methylation, a main epigenetic modification, plays an important role in the regulation of gene expression and is involved in the pathogenesis of autoimmune diseases. This work aims to investigate the effect of DNA demethylation on CD11a expression in SSc CD4 + T cells and to determine its functional significance. CD11a expression was measured using RT-PCR and flow cytometry. Bisulfite sequencing was used to determine the methylation status of the CD11a regulatory region. CD4 + T cells were co-cultured with antigen-presenting cells, B cells, or fibroblasts with and without anti-CD11a, and proliferation of CD4 + T cells, IgG production by B cells, and expression levels of COL1A2 mRNA by fibroblasts were evaluated. Results Elevated CD11a expression levels were observed in CD4 + T cells from SSc patients; these levels were found to be positively correlated with disease activity. The methylation levels of the CD11a regulatory sequences were lower in SSc patients than in controls and inversely correlated with CD11a mRNA expression. Treatment of CD4 + T cells with 5-azacytidine (5-azaC) decreased CD11a promoter methylation and caused CD11a overexpression. SSc CD4 + T cells and 5-azaC-treated CD4 + T cells showed increased proliferation of CD4 + T cells, increased production of IgG by co-cultured B cells, and induced expression of COL1A2 mRNA by co-cultured fibroblasts. These stimulatory effects were abrogated by anti-CD11a. Conclusions Demethylation of CD11a regulatory elements and subsequent CD11a overexpression in CD4 + T cells may mediate immunological abnormalities and fibrotic processes in SSc.

Role of Anti-Inflammatory Cytokines IL-4 and IL-13 in Systemic Sclerosis

The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis.

Biological functions and clinical implications of interleukin-34 in inflammatory diseases

Role of IL-33/ST2 Signaling Pathway in Systemic Sclerosis and Other Fibrotic Diseases.

Association of Interleukin 1 Family with Systemic Sclerosis

New insights into CD4(+) T cell abnormalities in systemic sclerosis.

The Role of CCL24 in Systemic Sclerosis

Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis

IL-21 drives skin and lung inflammation and fibrosis in a model for systemic sclerosis

IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis

CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis

Promotion of Myofibroblast Differentiation and Tissue Fibrosis by the Leukotriene B4–Leukotriene B4 Receptor Axis in Systemic Sclerosis

Roles of IL ‐1 and IL ‐10 family cytokines in the progression of systemic lupus erythematosus: Friends or foes?

Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis

Hypomethylation and overexpression of ITGAL (CD11a) in CD4 + T cells in systemic sclerosis

Immune Cell Dysregulation As a Mediator of Fibrosis in Systemic Sclerosis

Emerging Role of Interleukin-13 in Cardiovascular Diseases: A Ray of Hope.

Targeting cytokines and potentiality of JAK–STAT inhibition in systemic sclerosis

Role of NLRP3 inflammasome in systemic sclerosis

The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis

Changes in peripheral T-lymphocyte subsets and serum cytokines in patients with systemic sclerosis